

Mohawk Innovative Technology, Inc. Announces the Formation of MiTiHeart™ Corporation – Its First Subsidiary

Albany, NY (May 10, 2003) – Mohawk Innovative Technology, Inc., (MiTi®) a leader in oil-free, high speed bearing technology, announced today that it has established the MiTiHeart™ Corporation as its first wholly owned subsidiary to further develop and market its new blood pump designed for patients having congestive heart failure.

“We are ecstatic at the opportunity to prolong the life of patients suffering from debilitating heart disease using an advanced bearing technology that we developed for space application” said Dr. Hooshang Heshmat, President and Technical Director of MiTi®, who was personally involved in the design of the MiTiHeart™ blood pump.

According to the American Heart Association, approximately 4.5 million Americans have congestive heart failure (CHF) and nearly half a million new cases are reported every year. CHF is a chronic condition in which at least one chamber of the heart is not pumping well enough to meet the body’s need. Heart failure presents an increasing public burden of morbidity and mortality even as the mortality from coronary artery disease and hypertension is decreasing. While effective pharmacologic therapies have improved outcomes for mild to moderate CHF, the need for mechanical circulatory support is well defined and growing. According to estimates published in the Journal of Health Economics, at least 100,000 patients annually in the U.S. could benefit from fully implantable blood pumps. These mechanical devices are connected to the weak ventricle (usually the left ventricle) of the heart and assist the pumping action by forcing blood from ventricle to the aorta. As such, the term left ventricular assist device (LVAD) is often used to describe these mechanical blood pumps. Recent clinical studies have confirmed that the survival rate in patients with implanted LVADs is twice that of the control group undergoing drug therapy. Based on this information, the Medicaid Coverage Advisory Committee has recommended to the Centers for Medicare and Medicaid Services (CMS) to offer reimbursements for implantation of LVADs. The final decision by CMS, which is expected in a few months, will establish a clear market for treatment of heart failure with LVADs.

Dr. Said Jahanmir, has joined the MiTi®’s management team and will lead MiTiHeart™ Corporation as its President and CEO. Dr. Jahanmir is a technology leader with more than 30 years experience in R&D and technology management. Prior to this appointment, Dr. Jahanmir served on the MiTi®’s Board of Directors for two years. He received his Ph.D. from the Massachusetts Institute of Technology (Cambridge, MA) and has held technical and management position in academia, US government, and industry prior to joining MiTi®. His scientific and leadership contributions have been recognized by professional/technical societies with several prestigious awards.

Mohawk Innovative Technology, Inc., is a privately held company that develops and manufactures advanced bearing technology for high speed rotating machinery. The U.S. Small Business Administration (SBA) selected MiTi® to receive the annual 2002 Tibbetts Award, the agency’s highest national recognition for innovative technology. MiTi® offices and laboratories are located in Albany, NY. For further information visit <http://www.miti.cc>.

The MiTiHeart™ LVAD will be on display at the Annual Meeting of the American Society for Artificial Internal Organs in Washington DC, June 19-21, 2003. MiTiHeart™ Corporation is located in Gaithersburg in the heart of Maryland’s Biotech Alley. For additional information on MiTiHeart™, visit <http://www.mitiheart.com>.